GlassScriptPhysician profile
Ayisha Ilias
NPI 1538637046
$8,035.79
in general payments reported to CMS, 2019-2025
36 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,230 · 2022: $1,463 · 2023: $1,745 · 2024: $2,292 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,245 · Travel and Lodging: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.02 |
| Travel and Lodging | $1,098.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.42 | 2021-2025 | |
| Curonix LLC | $1,018.01 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic, INC. | $946.88 | 2021-2024 | Intellis Adaptivestim, Synchromedii |
| Vertos Medical, INC. | $851.44 | 2021-2024 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $628.27 | 2021-2025 | Belbuca, Xtampza |
| Saluda Medical Americas, INC. | $583.22 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $461.44 | 2022-2025 | Wavewriter Alpha Prime 16, General - Therapies, Spectra Wavewriter |
| Axonics, INC. | $289.26 | 2021 | |
| Tersera Therapeutics LLC | $197.39 | 2021-2025 | Prialt |
| Averitas Pharma INC. | $196.15 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $194.86 | 2021-2022 | |
| Biotronik Nro, INC. | $176.26 | 2025 | Prospera |
| Abbott Laboratories | $175.05 | 2022-2025 | Proclaim |
| Amgen INC. | $166.27 | 2021-2022 | |
| Pfizer INC. | $143.98 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $136.37 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $123.19 | 2021-2023 | Emgality, Reyvow |
| Almatica Pharma LLC | $106.16 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $71.51 | 2024-2025 | |
| Lundbeck LLC | $63.38 | 2024 | Vyepti |
| Bioventus LLC | $60.09 | 2022-2025 | Durolane |
| Teva Pharmaceuticals USA, INC. | $55.63 | 2021 | |
| Acacia Pharma INC | $42.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $40.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.30 | 2022 | |
| Si-Bone, INC. | $39.18 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $28.98 | 2021 | |
| Foundation Fusion Solutions, LLC | $26.28 | 2025 | |
| Convatec INC. | $23.26 | 2024 | |
| Forte Bio-Pharma LLC | $19.87 | 2024 | Prolate, Nalocet |
| Mdd US Operations, LLC | $17.81 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.98 | 2025 | |
| Amneal Pharmaceuticals LLC | $14.86 | 2023 | Lyvispah |
| Ibsa Pharma INC. | $13.91 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.54 | 2022 | |
| Relievant Medsystems, INC. | $10.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayisha Ilias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.